Microbiome Effect of Omadacycline on Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Microbiome changes
研究概览
简要总结
The goal of this study is to assess microbiome changes associated with omadacycline vs. comparators (moxifloxacin or oral vancomycin). Using a phase I study design, healthy volunteers aged 18-40 years will be given a 10-day course of either omadacycline 450 mg days 1 and 2 followed by 300 mg PO once daily, moxifloxacin 400 mg once daily, or oral vancomycin 125 mg given four times daily. Stool will be collected at baseline, daily during therapy, and at two follow-up time periods (days 13-14 and days 30-32). DNA will be extracted from stool and used for qPCR biomass and microbial metagenomic experiments. Results from the study will provide definitive data on the microbiome effects of omadacycline versus comparator antibiotics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Omadacycline
Subjects will receive 3 tablets on day 1 and day 2 (450 mg) followed by 2 tablets (300 mg) for days 3 through 10.
干预措施: Omadacycline (Drug)
Vancomycin (oral)
Vancomycin 125 mg capsules will be taken four times daily for a total of 10 days.
干预措施: Vancomycin Pill (Drug)
Moxifloxacin
Moxifloxacin 400 mg tablets will be taken once per day for a total of 10 days.
干预措施: Moxifloxacin (Drug)
结局指标
主要结局
Microbiome changes
时间窗: During dosing and 30 day follow up period
Metagenomic changes (16S rRNA) and qPCR for individual bacterial species
次要结局
未报告次要终点
研究者
Kevin W. Garey
Professor and Chair
University of Houston
